We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Turning Point Brands Inc | NYSE:TPB | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.35 | 0.64% | 55.35 | 365 | 12:12:21 |
Turning Point Brands, Inc. (“TPB” or “the Company”) (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products, including alternative smoking accessories and consumables with active ingredients, today announced financial results for the second quarter ended June 30, 2024.
Q2 2024 vs. Q2 2023
Graham Purdy, President and CEO, commented: “We were pleased by our second quarter results. We achieved our highest quarterly EBITDA since the second quarter of 2021. We believe Zig-Zag is on a sustainable growth trajectory, and Stoker’s MST continues to grow market share. In addition, sales of FRE, our modern oral nicotine pouch, grew 76% sequentially as we continue to expand our national footprint.”
Zig-Zag Products Segment (47% of total net sales in the quarter)
For the second quarter, Zig-Zag Products net sales increased 8.0% to $50.5 million driven by solid performance in our North American Papers & Wraps businesses as well as solid growth in cigars.
For the quarter, the Zig-Zag Products segment gross profit increased 1.7% to $26.9 million. Gross margin declined 330 basis points to 53.2% driven primarily by product mix.
“We are encouraged by our Zig-Zag results for the quarter,” said Purdy. “Our ongoing initiatives continue to demonstrate progress toward sustainably growing the Zig-Zag brand.”
Stoker’s Products Segment (39% of total net sales in the quarter)
For the second quarter, Stoker’s Products net sales increased 18.5% to $42.7 million. The segment was driven by high teens growth from MST and triple-digit growth off of a low base for FRE, partially offset by low-single-digit decline in loose-leaf tobacco. For the second quarter, total Stoker’s Products segment volume increased 5.3%, while price / mix increased 13.2%.
For the quarter, the Stoker’s Products segment gross profit increased 17.8% to $23.5 million. Gross margin contracted 30 basis points to 55.0%.
Performance Measures in the Second Quarter
Second quarter consolidated selling, general and administrative (“SG&A”) expenses were $32.8 million compared to $31.9 million in the second quarter of 2023.
The second quarter SG&A included the following notable items:
Total gross debt as of June 30, 2024 was $368.5 million. Net debt (total gross debt less unrestricted cash) as of June 30, 2024 was $226.4 million. The Company ended the quarter with total liquidity of $201.0 million, comprised of $142.2 million in cash and $58.8 million of asset backed revolving credit facility capacity.
On July 15, 2024, the Company retired the remaining $118.5 million of its convertible notes outstanding with cash on hand. Pro forma for retirement of the convertible notes as of June 30, 2024, the Company had gross debt outstanding of $250.0 million and net debt of $226.4 million.
During the quarter, the Company re-purchased 34,350 shares of common stock at a cost of $1.0 million.
2024 Outlook
The Company is increasing its previous full-year 2024 adjusted EBITDA guidance from $95 to $100 million to $98 to $102 million, which excludes CDS.
Creative Distribution Solutions (“CDS”) (14% of total net sales in the quarter)
For the second quarter, CDS net sales were $15.3 million, gross profit was $3.4 million, and gross margin was 22.5%.
Earnings Conference Call
As previously disclosed, a conference call with the investment community to review TPB’s financial results has been scheduled for 10:00 a.m. Eastern on Thursday, August 1, 2024. Investment community participants should dial in 10 minutes ahead of time using the toll-free number (888) 330-2502 (international participants should call (240) 789-2713 and follow the audio prompts after typing in the event ID: 6640134). A live listen-only webcast of the call will be available on the Events and Presentations section of the investor relations portion of the Company website (www.turningpointbrands.com). A replay of the webcast will be available on the site two hours following the call.
Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted accounting principles in the United States (GAAP), this press release includes certain non-GAAP financial measures including EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS and Adjusted Operating Income (Loss). A reconciliation of these non-GAAP financial measures accompanies this release.
About Turning Point Brands, Inc.
Turning Point Brands (NYSE: TPB) is a manufacturer, marketer and distributor of branded consumer products including alternative smoking accessories and consumables with active ingredients through its iconic Zig-Zag® and Stoker’s® brands. TPB’s products are available in more than 217,000 retail outlets in North America, and on sites such as www.zigzag.com. For the latest news and information about TPB and its brands, please visit www.turningpointbrands.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as "anticipate," "believe," "expect," "intend," "plan" and "will" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. As a result, these statements are not guarantees of future performance and actual events may differ materially from those expressed in or suggested by the forward-looking statements. Any forward-looking statement made by TPB in this press release, its reports filed with the Securities and Exchange Commission (the “SEC”) and other public statements made from time-to-time speak only as of the date made. New risks and uncertainties come up from time to time, and it is impossible for TPB to predict or identify all such events or how they may affect it. TPB has no obligation, and does not intend, to update any forward-looking statements after the date hereof, except as required by federal securities laws. Factors that could cause these differences include, but are not limited to those included in the Company’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed by the Company with the SEC. These statements constitute the Company’s cautionary statements under the Private Securities Litigation Reform Act of 1995.
Financial Statements Follow on Subsequent Pages
Turning Point Brands, Inc. Consolidated Statements of Income (dollars in thousands except share data) (unaudited)Three Months Ended June 30,
2024
2023
Net sales (1)
$
108,512
$
105,595
Cost of sales
54,671
53,117
Gross profit
53,841
52,478
Selling, general, and administrative expenses
32,753
31,933
Other operating income
(1,674
)
-
Operating income
22,762
20,545
Interest expense, net
2,991
4,019
Investment loss
2,439
4,080
Gain on extinguishment of debt
-
(600
)
Income before income taxes
17,332
13,046
Income tax expense
4,415
3,338
Consolidated net income
12,917
9,708
Net loss attributable to non-controlling interest
(87
)
(217
)
Net income attributable to Turning Point Brands, Inc.$
13,004
$
9,925
Basic income per common share: Net income attributable to Turning Point Brands, Inc.
$
0.74
$
0.56
Diluted income per common share: Net income attributable to Turning Point Brands, Inc.
$
0.68
$
0.53
Weighted average common shares outstanding: Basic
17,656,732
17,584,241
Diluted
20,156,854
20,409,943
(1) Net sales include excise taxes billed to customers of $0.8 million and $1.2 million for the three months ended June 30, 2024 and 2023, respectively. Turning Point Brands, Inc. Consolidated Balance Sheets (dollars in thousands except share data)
(unaudited)
June 30,
December 31,
ASSETS2024
2023
Current assets: Cash$
142,159
$
117,886
Accounts receivable, net of allowances of $54 in 2024 and $78 in 2023
12,557
9,989
Inventories, net
102,333
98,960
Other current assets
32,688
40,781
Total current assets
289,737
267,616
Property, plant, and equipment, net
26,441
25,300
Deferred income taxes
1,177
1,468
Right of use assets
10,305
11,480
Deferred financing costs, net
2,145
2,450
Goodwill
136,307
136,250
Other intangible assets, net
79,393
80,942
Master Settlement Agreement (MSA) escrow deposits
28,407
28,684
Other assets
17,644
15,166
Total assets
$
591,556
$
569,356
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable
$
11,919
$
8,407
Accrued liabilities
30,428
33,635
Current portion of long-term debt
118,470
58,294
Total current liabilities
160,817
100,336
Notes payable and long-term debt
247,960
307,064
Lease liabilities
8,834
9,950
Total liabilities
417,611
417,350
Commitments and contingencies Stockholders' equity: Preferred stock, $0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-
-
-
Common stock, voting, $0.01 par value; authorized shares, 190,000,000; 20,126,521 issued shares and 17,703,166 outstanding shares at June 30, 2024, and 19,922,137 issued shares and 17,605,677 outstanding shares at December 31, 2023
201
199
Common stock, nonvoting, $0.01 par value; authorized shares, 10,000,000; issued and outstanding shares -0-
-
-
Additional paid-in capital
121,948
119,075
Cost of repurchased common stock (2,423,355 shares at June 30, 2024, and 2,316,460 shares at December 31, 2023)
(81,144
)
(78,093
)
Accumulated other comprehensive loss
(3,072
)
(2,648
)
Accumulated earnings
134,917
112,443
Non-controlling interest
1,095
1,030
Total stockholders' equity
173,945
152,006
Total liabilities and stockholders' equity
$
591,556
$
569,356
Turning Point Brands, Inc. Consolidated Statements of Cash Flows (dollars in thousands) (unaudited)
Six Months Ended June 30,
2024
2023
Cash flows from operating activities: Consolidated net income$
25,096
$
17,050
Adjustments to reconcile net income to net cash provided by operating activities: Gain on extinguishment of debt
-
(1,377
)
Loss on sale of property, plant, and equipment
7
44
Loss on MSA investments
6
-
Depreciation and other amortization expense
1,916
1,535
Amortization of other intangible assets
1,559
1,542
Amortization of deferred financing costs
1,393
1,225
Deferred income tax expense
363
659
Stock compensation expense
3,951
2,836
Noncash lease income
(85
)
(29
)
Loss on investments
2,722
8,989
Changes in operating assets and liabilities: Accounts receivable
(2,489
)
456
Inventories
(3,218
)
(5,146
)
Other current assets
4,863
3,769
Other assets
(279
)
(4,548
)
Accounts payable
3,565
2,500
Accrued liabilities and other
(3,293
)
(1,972
)
Net cash provided by operating activities$
36,077
$
27,533
Cash flows from investing activities: Capital expenditures
$
(2,858
)
$
(2,993
)
Purchases of investments
(7,934
)
-
Proceeds from sale of investments
3,314
-
Purchases of non-marketable equity investments
(500
)
-
Restricted cash, MSA escrow deposits
4
-
Proceeds on the sale of property, plant and equipment
2
3
Net cash used in investing activities
$
(7,972
)
$
(2,990
)
Cash flows from financing activities: Convertible Senior Notes repurchased$
-
$
(27,357
)
Proceeds from call options
-
70
Payment of financing costs
(133
)
-
Payment of dividends
(2,407
)
(2,209
)
Exercise of options
900
406
Redemption of options
(4
)
(346
)
Redemption of restricted stock units
(840
)
-
Redemption of performance based restricted stock units
(1,212
)
(995
)
Common stock repurchased
(3,051
)
-
Net cash used in financing activities
$
(6,747
)
$
(30,431
)
Net increase (decrease) in cash$
21,358
$
(5,888
)
Effect of foreign currency translation on cash$
(76
)
$
(8
)
Cash, beginning of period: Unrestricted$
117,886
$
106,403
Restricted
4,929
4,929
Total cash at beginning of period
$
122,815
$
111,332
Cash, end of period: Unrestricted
$
142,159
$
100,507
Restricted
1,938
4,929
Total cash at end of period
$
144,097
$
105,436
Non-GAAP Financial Measures
To supplement our financial information presented in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, we use non-U.S. GAAP financial measures, including EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, and Adjusted Operating Income (Loss). We believe Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to our financial condition and results of operations. Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, and Adjusted Operating Income (Loss) are used by management to compare our performance to that of prior periods for trend analyses and planning purposes and are presented to our board of directors. We believe that EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, and Adjusted Operating Income (Loss) are appropriate measures of operating performance because they eliminate the impact of expenses that do not relate to business performance.
We define “EBITDA” as net income before interest expense, gain (loss) on extinguishment of debt, income tax expense, depreciation and amortization. We define “Adjusted EBITDA” as net income before interest expense, gain (loss) on extinguishment of debt, income tax expense, depreciation, amortization, other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Net Income” as net income excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Diluted EPS” as diluted earnings per share excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Operating Income (Loss)” as operating income excluding other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance.
Non-U.S. GAAP measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. EBITDA, Adjusted Net Income, Adjusted EBITDA, Adjusted Diluted EPS, and Adjusted Operating Income (Loss) exclude significant expenses that are required by U.S. GAAP to be recorded in our financial statements and is subject to inherent limitations. In addition, other companies in our industry may calculate this non-U.S. GAAP measure differently than we do or may not calculate it at all, limiting its usefulness as a comparative measure.
In accordance with SEC rules, we have provided, in the supplemental information attached, a reconciliation of the non-GAAP measures to the next directly comparable GAAP measures.
Schedule A Turning Point Brands, Inc. Reconciliation of GAAP Net Income to Adjusted EBITDA (dollars in thousands) (unaudited)Three Months Ended
June 30,
2024
2023
Net income attributable to Turning Point Brands, Inc.$
13,004
$
9,925
Add: Interest expense, net
2,991
4,019
Gain on extinguishment of debt
-
(600
)
Income tax expense
4,415
3,338
Depreciation expense
891
759
Amortization expense
931
771
EBITDA
$
22,232
$
18,212
Components of Adjusted EBITDA Corporate and CDS restructuring (a)
283
-
ERP/CRM (b)
489
138
Stock options, restricted stock, and incentives expense (c)
1,889
2,093
Transactional expenses and strategic initiatives (d)
97
82
FDA PMTA (e)
997
662
Non-cash asset impairment (f)
2,722
4,092
FET Refund (g)
(1,674
)
-
Adjusted EBITDA
$
27,035
$
25,279
(a)
Represents costs associated with corporate and CDS restructuring, including severance.(b)
Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses.(c)
Represents non-cash stock options, restricted stock, incentives expense and Solace performance stock units.(d)
Represents the fees incurred for transaction expenses.(e)
Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA"). The PMTA regime requires the Company to submit an application to the FDA to receive marketing authorization to continue to sell certain of its product lines with continued sales permitted during the pendency of the applications. The application is a onetime resource-intensive process for each covered product line; however, due to the nature of the implementation process for those product lines already in the market, applications can take multiple years to complete rather than the typical one-time submission. The Company currently has only two product lines currently subject to the PMTA process, having utilized other regulatory pathway options available for our other product lines. The Company does not expect to submit additional PMTA applications for any new product lines after the submission for the remaining two are complete.(f)
Represents impairment of investment assets.(g)
Represents a federal excise tax refund included in other operating income. Schedule B Turning Point Brands Reconciliation of GAAP Net Income to Adjusted Net Income and Diluted EPS to Adjusted Diluted EPS (dollars in thousands except share data) (unaudited)Three Months Ended
Three Months Ended
June 30, 2024
June 30, 2023
Income before income taxes
Income tax expense (h)
Net loss attributable to non- controlling interest
Adjusted Net Income
Adjusted Diluted EPS
Income before income taxes
Income tax expense (h)
Net loss attributable to non- controlling interest
Net Income
Diluted EPS
GAAP Net Income and Diluted EPS$
17,332
$
4,415
$
(87
)
$
13,004
$
0.68
$
13,046
$
3,338
$
(217
)
$
9,925
$
0.53
Gain on extinguishment of debt (a)
-
-
-
-
-
(600
)
(154
)
-
(446
)
(0.02
)
Corporate restructuring (b)
283
72
-
211
0.01
-
-
-
-
-
ERP/CRM (c)
489
125
-
364
0.02
138
35
-
103
0.01
Stock options, restricted stock, and incentives expense (d)
1,889
481
-
1,408
0.07
2,093
536
-
1,557
0.08
Transactional expenses and strategic initiatives (e)
97
25
-
72
0.00
82
21
-
61
0.00
FDA PMTA (f)
997
254
-
743
0.04
662
169
-
493
0.02
Non-cash asset impairment (g)
2,722
693
-
2,029
0.10
4,092
1,047
-
3,045
0.15
FET refund (i)
(1,674
)
(426
)
-
(1,248
)
(0.06
)
-
-
-
-
-
Tax benefit (j)
-
(577
)
-
577
0.03
-
(560
)
-
560
0.03
Adjusted Net Income and Adjusted Diluted EPS
$
22,135
$
5,062
$
(87
)
$
17,160
$
0.89
$
19,513
$
4,433
$
(217
)
$
15,297
$
0.79
Totals may not foot due to rounding
(a)
Represents gain on extinguishment of debt.(b)
Represents costs associated with corporate and CDS restructuring, including severance.(c)
Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses.(d)
Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs.(e)
Represents the fees incurred for transaction expenses.(f)
Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA"). The PMTA regime requires the Company to submit an application to the FDA to receive marketing authorization to continue to sell certain of its product lines with continued sales permitted during the pendency of the applications. The application is a onetime resource-intensive process for each covered product line; however, due to the nature of the implementation process for those product lines already in the market, applications can take multiple years to complete rather than the typical one-time submission. The Company currently has only two product lines currently subject to the PMTA process, having utilized other regulatory pathway options available for our other product lines. The Company does not expect to submit additional PMTA applications for any new product lines after the submission for the remaining two are complete.(g)
Represents impairment of investment assets.(h)
Income tax expense calculated using the effective tax rate for the quarter of 25.5% in 2024 and 25.6% in 2023.(i)
Represents a federal excise tax refund included in other operating income.(j)
Represents adjustment from quarterly tax rate to annual projected tax rate of 23% in 2024 and 2023. Schedule C Turning Point Brands, Inc. Reconciliation of GAAP Operating Income (Loss) to Adjusted Operating Income (Loss) (dollars in thousands) (unaudited)Consolidated
Zig-Zag Products
Stoker's Products
Creative Distribution Solutions
2nd Quarter
2nd Quarter
2nd Quarter
2nd Quarter
2nd Quarter
2nd Quarter
2nd Quarter
2nd Quarter
2024
2023
2024
2023
2024
2023
2024
2023
Net sales$
108,512
$
105,595
$
50,482
$
46,722
$
42,743
$
36,056
$
15,287
$
22,817
Gross profit$
53,841
$
52,478
$
26,872
$
26,422
$
23,524
$
19,968
$
3,445
$
6,088
Operating income (loss)
$
22,762
$
20,545
$
18,260
$
17,000
$
17,862
$
15,110
$
(108
)
$
460
Adjustments: Corporate restructuring
283
-
-
-
-
-
-
-
ERP/CRM
489
138
-
-
-
-
-
-
Transactional expenses and strategic initiatives
97
82
-
-
-
-
-
-
FDA PMTA
997
662
-
-
-
-
-
-
FET refund
(1,674
)
-
(1,674
)
-
-
-
-
-
Adjusted operating income (loss)
$
22,954
$
21,427
$
16,586
$
17,000
$
17,862
$
15,110
$
(108
)
$
460
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801150282/en/
Investor Contacts
Turning Point Brands, Inc. ir@tpbi.com
1 Year Turning Point Brands Chart |
1 Month Turning Point Brands Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions